VivoSeq
Musculoskeletal

Radius Fracture

25

Pipeline Programs

5

Active Trials

14

Companies Involved

Radius Fracture is an emerging landscape with 25 programs across 14 companies. The most active players are Novadip Biosciences, Almaject, Novartis. 9 therapies are approved with 7 more in late-stage development.

Pipeline Metrics

Competitive Density

50/100

Pipeline Velocity

6/100

Mech. Concentration

22/100

Completion Rate

86/100

Attrition Rate

10/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

Modality Breakdown

97%

Small molecule

33 of 34 classified programs — the dominant modality here.

3%ALL OTHERSPeptide13%

Small molecule leads; the ring shows all 34 classified programs, each share of the total. Modality classified for 100% of 34 pipeline programs.

Trial Status

21

clinical trials

Completed12 · 57%
Recruiting4 · 19%
Terminated2 · 10%
Unknown status2 · 10%
Not yet recruiting1 · 5%

Trial Activity

21 trials

Study Evaluating rhBMP-2/CPM in Closed Distal Radius Fractures
Completed·Pfizer logoPfizer·Phase 1·NCT00161629·40 enrolled
Effects of Teriparatide on Distal Radius Fracture Healing
Completed·Eli Lilly logoEli Lilly·Phase 2·NCT00190944·105 enrolled
Celecoxib in Postoperative Analgesia for Radius Fracture Surgery
Completed··Phase 4·NCT05288374·42 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)